← Eichor
Condition: Locally Advanced Gastric Or Gastroesophageal Junction Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Gastric Or Gastroesophageal Junction Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast
Phase 2 · 70 location(s) · AstraZeneca · NCT07069712Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · 106 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagog
Phase 2 · 18 location(s) · National Cancer Center, Japan · NCT07699939Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Phase N/A · 1 location(s) · Fudan University · NCT07389876Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction
Phase 2 · 44 location(s) · AstraZeneca · NCT05702229Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 · 6 location(s) · I-Mab Biopharma US Limited · NCT07432295Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Canc
Phase 2 · 5 location(s) · Xijing Hospital · NCT06576921XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07464756Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06650332A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Phase 3 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07673887Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Canc
Phase 3 · 1 location(s) · Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07522151Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NA · 15 location(s) · Tang-Du Hospital · NCT06128252Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2 · 1 location(s) · Peking University · NCT06023758IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT07025889A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastro
Phase 2/Phase 3 · 69 location(s) · Pfizer · NCT07392892A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction
Phase N/A · 13 location(s) · Astellas Pharma Korea, Inc. · NCT06902545
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.